Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Future Of Renal Denervation On Trial At ACC 2014 This Weekend

This article was originally published in The Gray Sheet

Executive Summary

The full results of Medtronic’s SYMPLICITY HTN-3 trial, to be presented at the American College of Cardiology Scientific Sessions on March 29, could determine the fate of the renal denervation devices under development by several major companies for drug-resistant hypertension.

You may also be interested in...

Medtronic Nabs First Superiority Outcome In TAVR Versus Surgery

Data from Medtronic’s CoreValve High Risk Study provide the firm with significant momentum toward expanding the FDA label for its transcatheter aortic valve replacement device. Based on the results, FDA says no advisory panel will need to meet for the firm’s high-risk surgery submission. Observers say the jury is still out on CoreValve versus Sapien question.

Full Medtronic Results Offer Little Reason For Optimism On Renal Denervation

Renal denervation did not have a significant effect on systolic blood pressure in the SYMPLICITY HTN-3 trial, the first major sham-controlled trial of renal denervation for drug-resistant hypertension. The trial’s sponsor, Medtronic, had previously announced that it missed its primary endpoint but full results of the study were presented for the first time at the ACC meeting in Washington, DC on March 29.

News Briefs: FDA Approves AF Catheter; Tax Reform Proposal; Renal Denervation

FDA approved a PMA supplement for Biosense Webster’s Thermocool SmartTouch, the first FDA-approved ablation catheter that can measure contact force in real time. J&J earns a CE mark for its Renlane renal denervation system. More news briefs.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts